CPX-351 is a liposomal formulation of daunorubicin plus cytarabine co-encapsulated at a molar ratio of 1:5 and it is designed to deliver synergistic drug ratios to leukemia cells.
- Gordon M.J. et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. Epub 2016 Dec 12;53:39-49. DOI: 10.1016/j.leukres.2016.12.002.